Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Receivables (2020 - 2025)

Harmony Biosciences Holdings' Change in Receivables history spans 6 years, with the latest figure at -$3.9 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 352.38% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached $13.8 million, up 54.66%, while the annual FY2025 figure was $13.8 million, 54.66% up from the prior year.
  • Change in Receivables for Q4 2025 was -$3.9 million at Harmony Biosciences Holdings, down from $7.7 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $22.9 million in Q1 2025 and bottomed at -$13.0 million in Q2 2025.
  • The 5-year median for Change in Receivables is $3.4 million (2022), against an average of $3.7 million.
  • The largest annual shift saw Change in Receivables skyrocketed 2215.69% in 2023 before it crashed 477.78% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $1.6 million in 2021, then crashed by 119.85% to -$325000.0 in 2022, then surged by 2215.69% to $6.9 million in 2023, then tumbled by 77.73% to $1.5 million in 2024, then plummeted by 352.38% to -$3.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Change in Receivables are -$3.9 million (Q4 2025), $7.7 million (Q3 2025), and -$13.0 million (Q2 2025).